Skip to main content
SpringerLink
Log in

Indikationen für Clozapin

  • Conference paper
Clozapin Pharmakologie und Klinik eines atypischen Neuroleptikums

  • 24 Accesses

Zusammenfassung

Die Indikationen für ein Medikament ergeben sich vor allem aus seinen Wirkungs-komponenten und seinem NebenwirkungsprofiL Für die genaue Charakterisierung ist es wichtig, wie sich Wirkungen und Nebenwirkungen einer Substanz von denjenigen anderer Präparate unterscheiden, für die die gleichen oder ähnliche Indikationen gelten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Angst J, Bente D, Heimann H, Helmchen H, Hippius H (1971a) Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-System. Pharmakopsychiatrie 4:200–211

    Google Scholar 

  • Angst J, Jaenicke U, Padrutt A, Scharfetter Ch (1971b) Ergebnisse eines Doppelblindversuches von HF 1854 (8-Chlor-11(4-methyl-l-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepin) im Vergleich zu Levomepromazin. Pharmakopsychiatrie 4:192–200

    Article  CAS  Google Scholar 

  • Axelrod S, Wetzler S (1989) Factors associated with better compliance with psychiatric aftercare. Hosp Community Psychiatry 40:397–401

    PubMed  CAS  Google Scholar 

  • Berzewski H, Helmchen H, Hippius H, Hoffman H, Kanowski S (1969) Das klinische Wirkungsspektrum eines neuen Dibenzdiazepin-Derivates. Arzneimittelforschung 19:496–498

    Google Scholar 

  • Caine ED, Polinsky RJ, Kartzinel R, Ebert MH (1979) The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 136:317–320

    PubMed  CAS  Google Scholar 

  • Gross H, Langner H (1970) Das Neuroleptikum 100–129/HF-1854 (Clozapin) in der Psychiatric. Int Pharmakopsychiatrie 4:220–230

    Google Scholar 

  • Johnson DAW (1977) Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia. Br J Hosp Med 17:564–569

    Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer HY and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpro-mazine. Arch Gen Psychiatry 45:789–796

    Article  PubMed  CAS  Google Scholar 

  • Kissling W, Kane JM, Barnes TRE, Dencker SJ, Fleichhacker WW, Goldstein MJ, Johnson DAW, Marder SR, Müller-Spann F, Tegeler J, Wistedt B, Woggon B (1991) Guidelines for neuroleptic relapse prevention in schizophrenia: towards a consensus view. In: Kissling W (ed) Guidelines for neuroleptic relapse Prevention. Springer, Berlin Heidelberg, pp 155–163

    Google Scholar 

  • Klimke A, Klieser E (1990) Das atypische Neuroleptikum Clozapin. Fundamenta Psychiatrica 4:190–202

    Google Scholar 

  • Kornhuber J (1992) (Potentielle) Antipsychotika mit neuartigen Wirkmechanismen. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd 4. Springer, Wien, pp 185–196

    Google Scholar 

  • Krupp P, Barnes P (1992) Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 160(Suppl 17) :38–40

    Google Scholar 

  • Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ (1990) HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in jewish patients with schizophrenia. Arch Gen Psychiatry 47:945–948

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS (1979) Effect of clozapine on human serum prolactin levels. Am J Psychiatry 136:1550–1555

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Luchins DJ (1984) Effect of clozapine in severe tardive dyskinesia: a case report. J Clin Pschopharmacol 4:286–287

    CAS  Google Scholar 

  • Morant J, Ruppaner H (1992) Arzneimittelkompendium der Schweiz. Documed, Basel

    Google Scholar 

  • Naber D, Hackl C, Marzelli B, Modell S, Boerner R, Koch HJ (1992) Zur subjektiven Wirkung von Clozapin (Leponex) im Vergleich zu typischen Neuroleptika. In: Naber D, Müller-Spahn F (Hrsg) Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums. Schattauer, Stuttgart New York, S 171–177

    Google Scholar 

  • Naber D, Hippius H (1990) The european experience with use of clozapine. Hospi Commun Psychiatry 41(8):886–890

    CAS  Google Scholar 

  • Sandell B, Eriksson L (1992) Patients’ experience with remoxipride — Results conveyed by patients in group meetings and individual interviews. Psychopharmacology 107 (Abstracts): B 12

    Google Scholar 

  • Stille G, Hippius H (1971) Kritische Stellungnahme zum Begriff der Neuroleptika (und von pharmakologischen und klinischen Befunden mit Clozapin). Pharmakopsychiatrie 4:182–191

    Article  CAS  Google Scholar 

  • Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31:67–72

    Article  PubMed  Google Scholar 

  • Veys PA, Wilkes S, Shah S, Noyelle R, Hoffbrand AV (1992) Clinical experience of clozapine-in-duced neutropenia in the UK. Laboratory investigation using liquid culture systems and immu-nofluorocytometry. Drug Safety 7 (Suppl 1) :26–32

    Article  PubMed  Google Scholar 

Download references

Authors
  1. B. Woggon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik, Universität München, Nußbaumstraße 7, 80336, München, Deutschland

    Dieter Naber  & Franz Müller-Spahn  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Woggon, B. (1994). Indikationen für Clozapin. In: Naber, D., Müller-Spahn, F. (eds) Clozapin Pharmakologie und Klinik eines atypischen Neuroleptikums. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93547-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93547-3_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-57206-0

  • Online ISBN: 978-3-642-93547-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation